United States securities and exchange commission logo

                            May 7, 2020

       Steven M. Fruchtman, M.D.
       Chief Executive Officer
       Onconova Therapeutics, Inc.
       375 Pheasant Run
       Newtown, PA 18940

                                                        Re: Onconova
Therapeutics, Inc.
Statement on Form S-3
                                                            Filed April 24,
                                                            File No. 333-237844

       Dear Dr. Fruchtman:

               We have limited our review of your registration statement to
those issues we have
       addressed in our comment. Please respond to this letter by amending your
registration statement
       and providing the requested information. If you do not believe our
comment applies to your
       facts and circumstances or do not believe an amendment is appropriate,
please tell us why in
       your response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Registration Statement on Form S-3 filed on April 24, 2020


   1.                                                   We note Onconova's
representation in correspondence to the staff dated November 12,
                                                        2019 at page 3 that the
company would "add the following risk factor disclosure
                                                        describing the
Company's forum selection provision and its intent in the Company's
                                                        future Annual Reports
on Form 10-K and in future registration statements," but are unable
                                                        to determine where you
have done so in either your Form 10-K for the fiscal year ended
                                                        December 31, 2019, or
in the instant registration statement on Form S-3. Please advise or
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

                                                        Refer to Rules 460 and
461 regarding requests for acceleration. Please allow adequate
 Steven M. Fruchtman, M.D.
Onconova Therapeutics, Inc.
May 7, 2020
Page 2

time for us to review any amendment prior to the requested effective date of
the registration

       Please contact Paul Fischer, Staff Attorney, at 202-551-3415 or Celeste
M. Murphy,
Legal Branch Chief, at 202-551-3257 with any questions.

FirstName LastNameSteven M. Fruchtman, M.D.
                                                             Division of
Corporation Finance
Comapany NameOnconova Therapeutics, Inc.
                                                             Office of Life
May 7, 2020 Page 2
cc:       Joanne Soslow, Esq.
FirstName LastName